Biota Pharmaceutical (BOTA) 1.55 $BOTA
Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
GlobeNewswire - Tue Jul 12, 6:00AM CDT
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced it is resuming enrollment in its Phase 2a challenge study of BTA585, an oral fusion inhibitor in development for the treatment and prevention of respiratory syncytial virus (RSV) infections.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections
GlobeNewswire - Thu May 26, 3:30PM CDT
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2a trial of BTA585 for the treatment of RSV infections being conducted in the U.K. This decision emanated from a lab report from one subject showing an increase of a cardiac enzyme level coupled with transient ECG changes, which led to a hospitalization of less than 24 hours. The subject's ECGs were normal prior to hospitalization and the cardiac enzyme levels returned to baseline shortly thereafter.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Aviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results
GlobeNewswire - Thu May 05, 3:02PM CDT
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) today announced its financial results for the three month period ended March 31, 2016, which is the third quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate and clinical developments.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Aviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners for Proceeds of $20 Million
GlobeNewswire - Mon Apr 25, 6:00AM CDT
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that it has signed a definitive agreement to receive a cash payment of $20 million from HealthCare Royalty Partners in exchange for an undisclosed portion of the Company's royalty rights related to Inavir, an inhaled neuraminidase inhibitor that is approved in Japan for the treatment and prevention of influenza. Aviragen plans to use the non-dilutive proceeds to advance its pipeline of direct-acting antivirals in development to treat infections that have limited therapeutic options.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Aviragen Therapeutics to Participate in FBR & Co. Healthcare Series Focused on Infectious Diseases
GlobeNewswire - Thu Apr 14, 3:01PM CDT
Aviragen Therapeutics, Inc., (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti, PhD, President & CEO of Aviragen Therapeutics, will participate in a panel discussion titled, "Notable Emerging Anti-Viral Agents" as part of the FBR & Co. New Prescriptions: Innovation in the Treatment of Diseases and Infections conference.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Biota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics, Inc. (NASDAQ: AVIR)
GlobeNewswire - Tue Apr 12, 6:00AM CDT
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., ("Aviragen Therapeutics"
, a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections that have limited therapeutic options.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Biota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, today announced the initiation of its Phase 2a challenge study of BTA585, an oral fusion inhibitor in development for the treatment and prevention of respiratory syncytial virus (RSV) infections. BTA585 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for RSV infections in infants, young children and adults.
BOTA: 1.55 (-0.04)
Biota Pharmaceuticals to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 8:00AM CDT
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate overview and update at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. ET in New York.
BOTA: 1.55 (-0.04)
Biota Pharmaceuticals to Present at 28th Annual ROTH Conference
GlobeNewswire - Mon Mar 07, 7:59AM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company" , a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate overview at the 28 Annual ROTH Conference on Monday, March 14, 2016 at 12:00 p.m. PT in Dana Point, CA.
BOTA: 1.55 (-0.04)
Biota Pharmaceuticals Reports Second Quarter Fiscal Year 2016 Financial Results
GlobeNewswire - Fri Feb 05, 6:00AM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced its financial results for the three month period ended December 31, 2015, which is the second quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate developments.
BOTA: 1.55 (-0.04)
Respiratory Syncytial Virus (RSV) Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5krjz7/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Respiratory Syncytial Virus (RSV) Infections Overview - Therapeutics Development - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - Folia Biotech Inc. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Globavir Biosciences, Inc. - Humabs BioMed SA - iBio, Inc. - ILiAD Biotechnologies, LLC - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Romark Laboratories, L.C. - Sirnaomics, Inc. - Spider Biotech - Spring Bank Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - The International Biotechnology Center (IBC) Generium - Vaxart, Inc. - VBI Vaccines Inc. For more information visit http://www.researchandmarkets.com/research/5k...espiratory
ADMA: 6.49 (-1.36), EBS: 30.97 (-2.42), BOTA: 1.55 (-0.04), VBIV: 3.79 (-0.01), GSK: 45.25 (+0.18), GILD: 80.46 (+0.99), MRK: 58.66 (unch), IBIO: 0.63 (+0.02)
Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Fiscal Year 2016 Financial Results on February 5, 2016
GlobeNewswire - Fri Jan 29, 8:00AM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company" , a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, February 5, 2016 at 9:00 a.m. ET to review the Company's financial results for the three month period ended December 31, 2015 and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.
BOTA: 1.55 (-0.04)
Biopharmaceutical Market - Forecast (2015 - 2020) - Market Dominated by North America
M2 - Wed Jan 20, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/9xxd67/biopharmaceutical) has announced the addition of the "Biopharmaceutical Market: By Source, By End Users (Hospitals & Others) - Forecast (2015 - 2020)" report to their offering. Biopharmaceuticals are large and complex products isolated from genetically modified living organisms. Recently, biologics or biopharmaceuticals is one of the fastest growing sectors of pharmaceutical industries, owing to its innovative nature, greater safety and efficacy compared to traditional drugs. The market for biopharmaceuticals is classified into three categories based on: - Source - Type of products - Application areas Each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biopharmaceuticals market. The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers. The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biopharmaceuticals market and future opportunities that can propel the market. Companies Mentioned: - Johnson & Johnson Private Limited - Roche Holding AG - Abbott Laboratories - Bristol-Myers Squibb - Novartis International AG - Genentech Inc - UCB - Merck Serono - Amgen - Eli Lilly & Co - Biogen Idec - Merck KGaA - ?lan Corporation - BioMarin Pharmaceutical Inc - AbbVie Inc - Invion Limited - AdAlta Pty Ltd - Admedus Ltd - Biota Pharmaceuticals Inc - Novozymes - Baxter International - APEIRON Biologics AG - Octapharma AG - Valneva SE - Genzyme - Mallinckrodt Pharmaceuticals - TM3 Therapeutics Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Market Forces 5. Market Strategic Analysis 6. Market - By Source 7. Market - By Products 8. Market - By Manufacturing Process 9. Market - By Application 10. Market - By End Users 11. Market - Geographic Analysis 12. Market Entropy 13. Company profiles 14. Appendix For more information visit http://www.researchandmarkets.com/research/9x...maceutical
ABT: 45.29 (+0.54), BIIB: 301.83 (+11.90), BMRN: 100.25 (+0.83), BOTA: 1.55 (-0.04), AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), BMY: 76.19 (+1.38), JNJ: 125.40 (+0.17), BAX: 48.50 (+0.48), MRK: 58.66 (unch), ABBV: 66.94 (+0.71), NVS: 83.07 (-0.19)
Global Genital Warts (Condylomata Acuminata) Therapeutics Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/ppm8zf/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Genital Warts (Condylomata Acuminata) Overview - Therapeutics Development - Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview - Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis - Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies - Genital Warts (Condylomata Acuminata) - Therapeutics under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Genital Warts (Condylomata Acuminata) - Products under Development by Companies - Genital Warts (Condylomata Acuminata) - Products under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development - Agilvax, Inc. - Biogenomics Limited - BioMAS Ltd. - Biota Pharmaceuticals, Inc. - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - Laboratories Ojer Pharma S.L. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Novan, Inc. - Novartis AG - Tamir Biotechnology, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/pp...ital_warts
BOTA: 1.55 (-0.04), FOMX: 8.01 (-0.51), NNVC: 1.74 (-0.01), NVS: 83.07 (-0.19)
Global Blood Plasma Market Growth of 10.54% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2015-2020
M2 - Mon Jan 18, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/q4rkcg/global_blood) has announced the addition of the "Global Blood Plasma Market: Trends, Opportunities and Forecasts (2015-2020) - (By Market Segment, Type of Blood Plasma -IVIG, Albumin, Factor VIII, By Region-North America, Europe, APAC, Market Entry Strategies for Global Players)" report to their offering. According to this research report the global blood plasma market is projected to exhibit a CAGR of 10.54% during 2015 - 2020. Few of the leading companies operating in blood plasma market in world include CSL Behring, Baxter, Grifols SA and Octapharma, etc. Benefits of this Report: - To gain an in-depth understanding of Global Blood Plasma Market - To identify the on-going trends and anticipated growth in the next five years - To help industry consultants, blood plasma manufacturers, suppliers and distributors align their market-centric strategies - To gain insights on the prevalent market entry strategies in blood plasma market for domestic as well as foreign companies - To obtain research based business decision and add weight to presentations and marketing material Companies Mentioned: - AMAG Pharmaceuticals, Inc. - Antares Pharma Inc - Baxter International Inc - BioDelivery Sciences International, Inc. - Biota Pharmaceuticals, Inc. - CSL Ltd. - Cipla - Emergent BioSolutions, Inc. - Grifols S.A - Octopharma Report Structure: 1. Research Methodology 2. Product Overview 3. Executive Summary 4. Global Blood Plasma Market: An Analysis 5. North America Blood Plasma Market: Size, Growth and Forecast 6. APAC Blood Plasma Market: Size, Growth and Forecast 7. Europe Blood Plasma Market: Size, Growth and Forecast 8. RoW Blood Plasma Market: Size, Growth and Forecast 9. Blood Plasma Market Trends 10. Global Blood Plasma Market Dynamics 11. Blood Plasma Market: Policy and Regulatory Landscape 12. Blood Plasma Market: Value Chain Analysis 13. Blood Plasma Trade Data Analysis 14. Blood Plasma Market: Porter's Five Force Analysis 15. Blood Plasma Market: Competitive landscape 16. Global Blood Plasma Market: Company Profiles 17. Strategic Recommendations For more information visit http://www.researchandmarkets.com/research/q4...obal_blood
BDSI: 2.41 (-0.14), EBS: 30.97 (-2.42), BOTA: 1.55 (-0.04), BAX: 48.50 (+0.48), AMAG: 27.02 (+0.49), ATRS: 1.03 (+0.03)
BioNap Consulting's Jason Napodano Interviewed by The Life Sciences Report
Marketwired - Fri Dec 18, 8:01AM CST
Before starting his own firm in July, Jason Napodano spent more than 12 years at Zacks Investment Research producing highly detailed small-cap biotechnology research. Today, as owner and senior analyst at BioNap Consulting, Napodano is doing much the same, but with more flexibility. He follows dozens of companies and continues to perform diligence on new names with the single goal of finding multibaggers. One of his themes is to take a biotech basket-of-stocks approach, since he knows some names will fail but the winners will move upward with momentum. In this interview with The Life Sciences Report, Napodano discusses small-cap names with the potential to power portfolios to extraordinary levels.
CANF: 2.10 (unch), BCT.VN: 0.230 (unch), RNN: 0.27 (+0.01), BOTA: 1.55 (-0.04)
Biota Announces Positive Phase 1 Data for Direct-Acting RSV Antiviral BTA585
GlobeNewswire - Fri Dec 18, 6:00AM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that it completed an initial Phase 1 single ascending dose (SAD) trial of BTA585, an oral respiratory syncytial virus (RSV) fusion inhibitor in development for the treatment and prevention of RSV infections. Top-line data demonstrated that BTA585 was generally well tolerated at all dose levels; there were no serious adverse events (AEs), and no drug-related clinically-significant changes in ECGs or clinical laboratory values were observed. The Company plans to present the full data from this trial at an upcoming scientific meeting in 2016.
BOTA: 1.55 (-0.04)
Prosthesis-Related Infections Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecast
M2 - Tue Dec 08, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/v3j6qv/prosthesisrelated) has announced the addition of the "Prosthesis-Related Infections Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Prosthesis-Related Infections Global Clinical Trials Review, H2, 2015" provides an overview of Prosthesis-Related Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Prosthesis-Related Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Sanofi - C. H. Boehringer Sohn AG & Co. KG - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v3...sisrelated
BOTA: 1.55 (-0.04)
Equites On the Move- Research on Aware, Biota Pharmaceuticals, Aldeyra Therapeutics and Northern Technologies
ACCESSWIRE - Thu Dec 03, 7:48AM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Aware Inc. (NASDAQ: AWRE), Biota Pharmaceuticals Inc. (NASDAQ: BOTA), Aldeyra Therapeutics Inc. (NASDAQ: ALDX) and Northern Technologies International Corp. (NASDAQ: NTIC). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ALDX: 6.00 (-0.15), BOTA: 1.55 (-0.04), NTIC: 14.06 (-0.34), AWRE: 4.79 (unch)
Biota Pharmaceuticals to Present at Stifel 2015 Healthcare Conference
GlobeNewswire - Wed Nov 11, 3:01PM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company" , a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate overview at the Stifel 2015 Healthcare Conference on Wednesday, November 18, 2015 at 3:45 p.m. ET in New York, NY.
BOTA: 1.55 (-0.04)
Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
GlobeNewswire - Tue Jul 12, 6:00AM CDT
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced it is resuming enrollment in its Phase 2a challenge study of BTA585, an oral fusion inhibitor in development for the treatment and prevention of respiratory syncytial virus (RSV) infections.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections
GlobeNewswire - Thu May 26, 3:30PM CDT
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2a trial of BTA585 for the treatment of RSV infections being conducted in the U.K. This decision emanated from a lab report from one subject showing an increase of a cardiac enzyme level coupled with transient ECG changes, which led to a hospitalization of less than 24 hours. The subject's ECGs were normal prior to hospitalization and the cardiac enzyme levels returned to baseline shortly thereafter.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Aviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results
GlobeNewswire - Thu May 05, 3:02PM CDT
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) today announced its financial results for the three month period ended March 31, 2016, which is the third quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate and clinical developments.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Aviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners for Proceeds of $20 Million
GlobeNewswire - Mon Apr 25, 6:00AM CDT
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that it has signed a definitive agreement to receive a cash payment of $20 million from HealthCare Royalty Partners in exchange for an undisclosed portion of the Company's royalty rights related to Inavir, an inhaled neuraminidase inhibitor that is approved in Japan for the treatment and prevention of influenza. Aviragen plans to use the non-dilutive proceeds to advance its pipeline of direct-acting antivirals in development to treat infections that have limited therapeutic options.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Aviragen Therapeutics to Participate in FBR & Co. Healthcare Series Focused on Infectious Diseases
GlobeNewswire - Thu Apr 14, 3:01PM CDT
Aviragen Therapeutics, Inc., (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti, PhD, President & CEO of Aviragen Therapeutics, will participate in a panel discussion titled, "Notable Emerging Anti-Viral Agents" as part of the FBR & Co. New Prescriptions: Innovation in the Treatment of Diseases and Infections conference.
BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Biota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics, Inc. (NASDAQ: AVIR)
GlobeNewswire - Tue Apr 12, 6:00AM CDT
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., ("Aviragen Therapeutics"
, a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections that have limited therapeutic options. BOTA: 1.55 (-0.04), AVIR: 1.35 (-0.02)
Biota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, today announced the initiation of its Phase 2a challenge study of BTA585, an oral fusion inhibitor in development for the treatment and prevention of respiratory syncytial virus (RSV) infections. BTA585 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for RSV infections in infants, young children and adults.
BOTA: 1.55 (-0.04)
Biota Pharmaceuticals to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 8:00AM CDT
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate overview and update at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. ET in New York.
BOTA: 1.55 (-0.04)
Biota Pharmaceuticals to Present at 28th Annual ROTH Conference
GlobeNewswire - Mon Mar 07, 7:59AM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"
, a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate overview at the 28 Annual ROTH Conference on Monday, March 14, 2016 at 12:00 p.m. PT in Dana Point, CA. BOTA: 1.55 (-0.04)
Biota Pharmaceuticals Reports Second Quarter Fiscal Year 2016 Financial Results
GlobeNewswire - Fri Feb 05, 6:00AM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced its financial results for the three month period ended December 31, 2015, which is the second quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate developments.
BOTA: 1.55 (-0.04)
Respiratory Syncytial Virus (RSV) Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5krjz7/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Respiratory Syncytial Virus (RSV) Infections Overview - Therapeutics Development - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - Folia Biotech Inc. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Globavir Biosciences, Inc. - Humabs BioMed SA - iBio, Inc. - ILiAD Biotechnologies, LLC - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Romark Laboratories, L.C. - Sirnaomics, Inc. - Spider Biotech - Spring Bank Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - The International Biotechnology Center (IBC) Generium - Vaxart, Inc. - VBI Vaccines Inc. For more information visit http://www.researchandmarkets.com/research/5k...espiratory
ADMA: 6.49 (-1.36), EBS: 30.97 (-2.42), BOTA: 1.55 (-0.04), VBIV: 3.79 (-0.01), GSK: 45.25 (+0.18), GILD: 80.46 (+0.99), MRK: 58.66 (unch), IBIO: 0.63 (+0.02)
Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Fiscal Year 2016 Financial Results on February 5, 2016
GlobeNewswire - Fri Jan 29, 8:00AM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"
, a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, February 5, 2016 at 9:00 a.m. ET to review the Company's financial results for the three month period ended December 31, 2015 and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call. BOTA: 1.55 (-0.04)
Biopharmaceutical Market - Forecast (2015 - 2020) - Market Dominated by North America
M2 - Wed Jan 20, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/9xxd67/biopharmaceutical) has announced the addition of the "Biopharmaceutical Market: By Source, By End Users (Hospitals & Others) - Forecast (2015 - 2020)" report to their offering. Biopharmaceuticals are large and complex products isolated from genetically modified living organisms. Recently, biologics or biopharmaceuticals is one of the fastest growing sectors of pharmaceutical industries, owing to its innovative nature, greater safety and efficacy compared to traditional drugs. The market for biopharmaceuticals is classified into three categories based on: - Source - Type of products - Application areas Each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biopharmaceuticals market. The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers. The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biopharmaceuticals market and future opportunities that can propel the market. Companies Mentioned: - Johnson & Johnson Private Limited - Roche Holding AG - Abbott Laboratories - Bristol-Myers Squibb - Novartis International AG - Genentech Inc - UCB - Merck Serono - Amgen - Eli Lilly & Co - Biogen Idec - Merck KGaA - ?lan Corporation - BioMarin Pharmaceutical Inc - AbbVie Inc - Invion Limited - AdAlta Pty Ltd - Admedus Ltd - Biota Pharmaceuticals Inc - Novozymes - Baxter International - APEIRON Biologics AG - Octapharma AG - Valneva SE - Genzyme - Mallinckrodt Pharmaceuticals - TM3 Therapeutics Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Market Forces 5. Market Strategic Analysis 6. Market - By Source 7. Market - By Products 8. Market - By Manufacturing Process 9. Market - By Application 10. Market - By End Users 11. Market - Geographic Analysis 12. Market Entropy 13. Company profiles 14. Appendix For more information visit http://www.researchandmarkets.com/research/9x...maceutical
ABT: 45.29 (+0.54), BIIB: 301.83 (+11.90), BMRN: 100.25 (+0.83), BOTA: 1.55 (-0.04), AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), BMY: 76.19 (+1.38), JNJ: 125.40 (+0.17), BAX: 48.50 (+0.48), MRK: 58.66 (unch), ABBV: 66.94 (+0.71), NVS: 83.07 (-0.19)
Global Genital Warts (Condylomata Acuminata) Therapeutics Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/ppm8zf/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Genital Warts (Condylomata Acuminata) Overview - Therapeutics Development - Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview - Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis - Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies - Genital Warts (Condylomata Acuminata) - Therapeutics under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Genital Warts (Condylomata Acuminata) - Products under Development by Companies - Genital Warts (Condylomata Acuminata) - Products under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development - Agilvax, Inc. - Biogenomics Limited - BioMAS Ltd. - Biota Pharmaceuticals, Inc. - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - Laboratories Ojer Pharma S.L. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Novan, Inc. - Novartis AG - Tamir Biotechnology, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/pp...ital_warts
BOTA: 1.55 (-0.04), FOMX: 8.01 (-0.51), NNVC: 1.74 (-0.01), NVS: 83.07 (-0.19)
Global Blood Plasma Market Growth of 10.54% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2015-2020
M2 - Mon Jan 18, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/q4rkcg/global_blood) has announced the addition of the "Global Blood Plasma Market: Trends, Opportunities and Forecasts (2015-2020) - (By Market Segment, Type of Blood Plasma -IVIG, Albumin, Factor VIII, By Region-North America, Europe, APAC, Market Entry Strategies for Global Players)" report to their offering. According to this research report the global blood plasma market is projected to exhibit a CAGR of 10.54% during 2015 - 2020. Few of the leading companies operating in blood plasma market in world include CSL Behring, Baxter, Grifols SA and Octapharma, etc. Benefits of this Report: - To gain an in-depth understanding of Global Blood Plasma Market - To identify the on-going trends and anticipated growth in the next five years - To help industry consultants, blood plasma manufacturers, suppliers and distributors align their market-centric strategies - To gain insights on the prevalent market entry strategies in blood plasma market for domestic as well as foreign companies - To obtain research based business decision and add weight to presentations and marketing material Companies Mentioned: - AMAG Pharmaceuticals, Inc. - Antares Pharma Inc - Baxter International Inc - BioDelivery Sciences International, Inc. - Biota Pharmaceuticals, Inc. - CSL Ltd. - Cipla - Emergent BioSolutions, Inc. - Grifols S.A - Octopharma Report Structure: 1. Research Methodology 2. Product Overview 3. Executive Summary 4. Global Blood Plasma Market: An Analysis 5. North America Blood Plasma Market: Size, Growth and Forecast 6. APAC Blood Plasma Market: Size, Growth and Forecast 7. Europe Blood Plasma Market: Size, Growth and Forecast 8. RoW Blood Plasma Market: Size, Growth and Forecast 9. Blood Plasma Market Trends 10. Global Blood Plasma Market Dynamics 11. Blood Plasma Market: Policy and Regulatory Landscape 12. Blood Plasma Market: Value Chain Analysis 13. Blood Plasma Trade Data Analysis 14. Blood Plasma Market: Porter's Five Force Analysis 15. Blood Plasma Market: Competitive landscape 16. Global Blood Plasma Market: Company Profiles 17. Strategic Recommendations For more information visit http://www.researchandmarkets.com/research/q4...obal_blood
BDSI: 2.41 (-0.14), EBS: 30.97 (-2.42), BOTA: 1.55 (-0.04), BAX: 48.50 (+0.48), AMAG: 27.02 (+0.49), ATRS: 1.03 (+0.03)
BioNap Consulting's Jason Napodano Interviewed by The Life Sciences Report
Marketwired - Fri Dec 18, 8:01AM CST
Before starting his own firm in July, Jason Napodano spent more than 12 years at Zacks Investment Research producing highly detailed small-cap biotechnology research. Today, as owner and senior analyst at BioNap Consulting, Napodano is doing much the same, but with more flexibility. He follows dozens of companies and continues to perform diligence on new names with the single goal of finding multibaggers. One of his themes is to take a biotech basket-of-stocks approach, since he knows some names will fail but the winners will move upward with momentum. In this interview with The Life Sciences Report, Napodano discusses small-cap names with the potential to power portfolios to extraordinary levels.
CANF: 2.10 (unch), BCT.VN: 0.230 (unch), RNN: 0.27 (+0.01), BOTA: 1.55 (-0.04)
Biota Announces Positive Phase 1 Data for Direct-Acting RSV Antiviral BTA585
GlobeNewswire - Fri Dec 18, 6:00AM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that it completed an initial Phase 1 single ascending dose (SAD) trial of BTA585, an oral respiratory syncytial virus (RSV) fusion inhibitor in development for the treatment and prevention of RSV infections. Top-line data demonstrated that BTA585 was generally well tolerated at all dose levels; there were no serious adverse events (AEs), and no drug-related clinically-significant changes in ECGs or clinical laboratory values were observed. The Company plans to present the full data from this trial at an upcoming scientific meeting in 2016.
BOTA: 1.55 (-0.04)
Prosthesis-Related Infections Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecast
M2 - Tue Dec 08, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/v3j6qv/prosthesisrelated) has announced the addition of the "Prosthesis-Related Infections Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Prosthesis-Related Infections Global Clinical Trials Review, H2, 2015" provides an overview of Prosthesis-Related Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Prosthesis-Related Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Sanofi - C. H. Boehringer Sohn AG & Co. KG - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v3...sisrelated
BOTA: 1.55 (-0.04)
Equites On the Move- Research on Aware, Biota Pharmaceuticals, Aldeyra Therapeutics and Northern Technologies
ACCESSWIRE - Thu Dec 03, 7:48AM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Aware Inc. (NASDAQ: AWRE), Biota Pharmaceuticals Inc. (NASDAQ: BOTA), Aldeyra Therapeutics Inc. (NASDAQ: ALDX) and Northern Technologies International Corp. (NASDAQ: NTIC). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ALDX: 6.00 (-0.15), BOTA: 1.55 (-0.04), NTIC: 14.06 (-0.34), AWRE: 4.79 (unch)
Biota Pharmaceuticals to Present at Stifel 2015 Healthcare Conference
GlobeNewswire - Wed Nov 11, 3:01PM CST
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"
, a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate overview at the Stifel 2015 Healthcare Conference on Wednesday, November 18, 2015 at 3:45 p.m. ET in New York, NY. BOTA: 1.55 (-0.04)
